New Delhi, April 15 -- India's healthcare sector is poised for high single-digit year-on-year revenue growth in Q4FY26, but EBITDA margins are set to "materially correct" as the loss of exclusivity in gRevlimid and rising cost pressures weigh on profitability, according to a research report by brokerage firm Systematix.

"For 4QFY26, companies within our healthcare universe are expected to deliver high single-digit YoY revenue growth. However, EBITDA margins will materially correct," the report said. Median growth is estimated at 12% for revenue and 3.6% for EBITDA, with net earnings likely witnessing a 14% decline.

The loss of exclusivity in gRevlimid is the single largest drag on earnings this quarter. "The primary driver of this year ...